Table 1.
Clinical characteristics of the men in each of the studies contributing to the PRACTICAL consortium (n = 41,062)
| Study | Country | n | Mean | % | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Controls | Cases | Age at diagnosis (years) | PSA at diagnosis (ng/ml) | Screen detectedb (%) | Family history prostate cancer | Gleason score 8–10 | Advanced stage (T3 or T4) | Distant spread (SEER) | ||
| CPCS1 | Denmark | 2,771 | 848 | 69.5 | 48.0 | 0.0 | 8.2 | 35.0 | – | – |
| CPCS2 | Denmark | 1,009 | 265 | 64.9 | 36.0 | 0.0 | 14.7 | 10.6 | – | – |
| EPIC | Europea | 1,079 | 722 | 64.9 | 19.7 | 0.0 | – | 3.6 | 3.8 | 0.9 |
| ESTHER | Germany | 318 | 313 | 65.5 | 58.7 | 61.9 | 8.9 | 9.1 | 26.4 | 3.4 |
| FHCRC | USA | 730 | 761 | 59.7 | 16.1 | – | 21.7 | 10.4 | – | 2.6 |
| IPO-Porto | Portugal | 66 | 183 | 59.3 | 8.3 | 82.8 | 20.0 | 15.8 | 64.5 | 0.0 |
| MAYO | USA | 488 | 767 | 65.2 | 15.5 | 73.7 | 29.1 | 33.0 | 44.4 | 0.5 |
| MCCS | Australia | 1,169 | 1,698 | 58.5 | 136.6 | – | 23.4 | 11.0 | 14.0 | 0.8 |
| MEC | USA | 829 | 819 | 69.5 | – | – | 13.0 | 36.0 | – | 2.8 |
| MOFFITT | USA | 100 | 412 | 64.9 | 7.3 | 0.0 | 22.9 | 11.2 | 3.5 | 0.5 |
| PCMUS | Bulgaria | 140 | 151 | 69.3 | 32.5 | 21.2 | 5.3 | 29.8 | 42.4 | 18.5 |
| PPF-UNIS | UK | 176 | 244 | 68.9 | 32.0 | – | 25.3 | 10.9 | 25.7 | 9.0 |
| Poland | Poland | 359 | 438 | 67.7 | 40.2 | 0.0 | 10.6 | 14.0 | 36.8 | 2.8 |
| ProMPT | UK | 1 | 166 | 66.3 | 33.0 | 0.0 | 34.6 | 18.9 | 32.7 | 7.8 |
| ProtecT | UK | 1,474 | 1,542 | 62.8 | 9.6 | 100.0 | 7.9 | 5.7 | 11.3 | 0.4 |
| QLD/ProsCan | Australia | 87 | 186 | 61.3 | 6.7 | – | 36.2 | 4.0 | 0.0 | 0.0 |
| STHMI | Sweden | 2,224 | 2,002 | 66.2 | – | – | 20.2 | 10.2 | 14.2 | 1.6 |
| TAMPERE | Finland | 2,413 | 2,753 | 68.2 | 69.1 | 46.8 | – | 15.4 | 21.0 | 7.3 |
| UKGPCS | UK | 4,182 | 4,549 | 63.8 | 83.9 | 28.9 | 23.4 | 17.2 | 32.9 | 10.7 |
| ULM | Germany | 354 | 601 | 63.8 | 19.1 | – | 44.9 | 15.5 | 39.9 | 1.1 |
| UTAH | USA | 245 | 440 | 62.6 | – | – | 51.4 | 16.1 | – | 4.7 |
| WUGS | USA | 0 | 988 | 60.8 | 6.2 | – | 42.3 | 7.9 | 24.2 | 0.1 |
Studies: Copenhagen Prostate Cancer Study 1 (CPCS1); Copenhagen Prostate Cancer Study 2 (CPCS2); European Prospective Investigation Into Cancer and Nutrition (EPIC); Epidemiological investigations of the chances of preventing, recognizing early and optimally treating chronic diseases in an elderly population (ESTHER); Fred Hutchinson Cancer Research Center (FHCRC); Portuguese Oncology Institute, Porto (IPO-Porto); Mayo Clinic (MAYO); Melbourne Collaborative Cohort Study (MCCS); Multiethnic Cohort Study (MEC); The Moffitt Group (MOFFITT); Prostate Cancer study Medical University Sofia (PCMUS); Prostate Project Foundation-Postgraduate Medical School, Surrey (PPF-UNIS); The Poland Group (Poland); Prostate cancer: Mechanisms of progression and Treatment (ProMPT); Prostate testing for cancer and Treatment (ProtecT); Retrospective Queensland Study (QLD) and the Prostate Cancer Supportive Care and Patient Outcomes Project (ProsCan); Stockholm 1 (STHMI); Finnish Genetic Predisposition to Prostate Cancer Study (TAMPERE); U.K. Genetic Prostate Cancer Study and The Prostate Cancer Research Foundation Study (UKGPCS); Familial Prostate Cancer Study Ulm (ULM); UTAH Study (UTAH); Washington University Genetics Study (WUGS)
aGermany, Greece, Italy, Netherlands, Spain, Sweden, Oxford
bStudies with 0 % screen detected are entirely based on clinically detected cases, and studies with no information about method of detection have a missing value; 12,231 individuals have information of method of detection